Prevents pregnancy. ANDA 90538, held by Glenmark Pharms Ltd. Ethinyl Estradiol; Norethindrone.
As of Nov 16, 2026, ANDA 90538 (Briellyn), held by Glenmark Pharms Ltd, was first approved by FDA on Mar 22, 2011, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 22, 2011 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Briellyn0.035MG;0.4MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone | Rx |
| Apr 29, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 9, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 25, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 22, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters